China Biopharma Strikes Deal for Antiviral

by Richard Daverman, PhD
ChinaBio Today



HPV Herbal Drug Will Seek OTC Approval in US, Europe

China Biopharma (Bulletin Board: CBPC) signed a deal with Soonfast Pharmaceutical Service & Technology Co., Ltd., allowing China Biopharma to introduce an antiviral medicine for human papillomavirus (HPV) and herpes simplex virus (HSV) in the US and Europe.

The medication is a natural, topical drug that has been shown in tests to inhibit the growth of HPV and HSV. In two to three days, it has reduced the infection from the virus by 90%. In experiments, the herbal drug has killed all of the HPV types 6/11/16/18 and 33.

HPVs are the most common sexually transmitted viral agents in the US. They have infected up to 20% of the people aged 15 to 49. No currently available drug completely eliminates the infection.

China Biopharma and Soonfast will join in conducting tests in China and the US to obtain regulatory permission to market the herbal drug as an OTC medication.

Terms of the agreement were not disclosed.

At present, China Biopharma makes and distributes vaccines in China (see story). Its products target influenza, hemorrhagic fever, and Japanese Encephalitis.



RELATED READING:
- China Meditech Pays $3.3 Million for R&D Facility
- Chi-Med Rumoured Close to Signing Major Deal
- Shijiazhuang Pharma Bought by Legend, Goldman Sachs



ChinaBio Today is a regular contributor to BioHealth Investor
_______________